Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRK

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

Merck Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29.

Benzinga

What You Need To Know Ahead of Merck's Earnings Release

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Barchart

Is Merck Stock Underperforming the Nasdaq?

Despite Merck’s recent underperformance relative to the Nasdaq, analysts remain moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Are Wall Street Analysts Bullish on Merck Stock?

While Merck has trailed the broader market over the past year, analysts still see a reasonably promising path ahead for the pharma heavyweight.

Barchart

Do Wall Street Analysts Like Pfizer Stock?

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Streak Analysis Alert: Why Merck (MRK) Should Be on Your Radar This Week

Blue chips like MRK stock generally represent a 50/50 wager for any given week. However, certain conditions strongly tilt the odds toward one side of the spectrum.

Barchart

What to Expect From Merck & Co.'s Next Quarterly Earnings Report

Merck & Co. will release its first-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Merck Stock Just Reminded Us Why ‘Buy the Dip’ Is Not That Simple

This healthcare company is down more than 30% over the past 52 weeks but still may not be a good buy for value investors.

Barchart

Institutional Investors Bet $1B on These 4 Stocks—Should You?

Institutional investors snapped up at least $1 billion in shares of each of these four companies in Q4 of 2024 - should you buy as well?

MarketBeat

These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?

This article covers three stocks included in the S&P 500 which are showing exceptionally low P/E ratios of 20 or less, indicating potential buys.

MarketBeat

Is Merck Stock Underperforming the S&P 500?

Despite Merck’s recent underperformance relative to the S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

MarketBeat Week in Review – 02/10 - 02/14

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

MarketBeat

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat

Stock Market Today: Earnings Speak Louder Than Tariffs

Recent market reaction to Trump administration policy announcements has been "entirely normal."

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 High-Conviction Stocks with Strong Buy Ratings from Analysts

It’s easy to get caught up in market noise, but investing in companies backed by strong fundamentals and long-term growth potential can help investors stay the course even during market volatility. Thus, one could consider adding these three high-conviction pharmaceutical stocks, AbbVie (ABBV), Merck & Co. (MRK), and Bristol-Myers Squibb…

Barchart

What Are Wall Street Analysts’ Target Price for Merck Stock?

Merck has considerably underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Barchart

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

Barchart

What to Expect From Merck & Co.'s Q4 2024 Earnings Report

Merck & Co. is scheduled to announce its fourth-quarter results next month, with analysts anticipating significant earnings growth.

Barchart

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

StockNews.com

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from…

StockNews.com

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

Barchart

How Is Merck's Stock Performance Compared to Other Pharmaceuticals Stocks?

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Benzinga

Merck & Co Unusual Options Activity For December 02

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

1 2 3 4 5

People

Gabriel OsorioMazilli

50 stories

Jea Yu

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.